FBLG
FibroBiologics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.02M
P/E Ratio
—
EPS
$-7.02
Beta
1.15
52W High
$17.20
52W Low
$0.91
50-Day MA
$1.24
200-Day MA
$5.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. is an innovative biotechnology company leading advancements in regenerative medicine through the application of fibroblast cells to treat degenerative diseases and spinal disorders. The company's robust intellectual property portfolio enhances its strategic position within the competitive cellular therapy sector, and it prioritizes clinical excellence and innovation. By engaging in strategic collaborations and fostering active research initiatives, FibroBiologics is dedicated to transforming healthcare and enhancing patient outcomes with its cutting-edge therapeutic solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.93M |
| Operating Margin | 0.00% |
| Return on Equity | -755.00% |
| Return on Assets | -123.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.74 |
| Price-to-Book | 1.93 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.21M |
| Float | $4.57M |
| % Insiders | 12.62% |
| % Institutions | 12.52% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Analyst Ratings
Consensus ($13.50 target)
1
Strong Buy1
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026